No abstract

No abstract

The 2-(5-methyl-2-furyl)-1H-benzimidazole moiety has shown promising activity against vascular endothelial growth factor (VEGF)-induced angiogenesis. In part I of this study, we have synthesized new analogs and tested their anti-angiogenic potentials. Here, we continue our previous study with different new analogs. Some compounds show promising cytotoxic activity against the human breast cancer cell line MCF-7, with IC50 in the range of 7.80-13.90 µg/mL, and exhibited remarkable in vitro inhibition against VEGF in the MCF-7 cancer cell line, with 95-98% of inhibition in comparison to tamoxifen as reference (IC50: 8.00 µg/mL, % of inhibition = 98%). Additionally, a molecular docking study was carried out to gain insight into plausible binding modes and to understand the structure-activity relationships of the synthesized compounds.

No abstract

A series of bis‐1,3‐thiazine derivatives 3a–o were synthesized from the condensation reactions of symmetric dialdehydes 1a–c possessing aliphatic ether spacer units with 3‐substituted‐amino‐2‐cyano‐3‐mercaptoacrylamides 2a–e. The chemical structures of the products were fully characterized by using different spectroscopic techniques, such as 1H NMR, 13C NMR, IR, electron impact mass spectrometry, and elemental analysis. Compounds 3a, 3f, and 3k underwent ring opening followed by recyclization and alkylation in basic medium to afford bis‐pyrimidinones 4a–c and 5a–c. The anticancer potential of the new bis‐1,3‐thiazines was assessed in vitro against six different human cell lines, including lung A549, colon HCT116, breast MCF‐7, prostate PC3, liver HepG2, and normal melanocyte HFB4. The results revealed a potent activity of compounds 3e and 3k against breast and liver cancer cell lines in comparison with the reference drug doxorubicin with no noticeable toxicity on normal cells.

No abstract

No abstract

No abstract